Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
MomentumIts trading last trade up | glenn1919 | investorshub | 09/20/2023 4:55:01 AM |
$OKYO bears and bulls | Boris the Spider | investorshub | 09/20/2023 12:57:26 AM |
$OKYO bulls and bears | mfayman | investorshub | 09/19/2023 11:56:09 PM |
$OKYO great article | Sirpeter | investorshub | 09/19/2023 11:31:38 PM |
$OKYO Do we have a winner?Turn around time? | Count Crypto | investorshub | 09/19/2023 10:10:34 PM |
$OKYO Anyone hear anything lately? Want to see this one go | Count Crypto | investorshub | 09/19/2023 9:47:05 PM |
Price gaining | Pisd | investorshub | 09/19/2023 8:49:50 PM |
Price gaining | glenn1919 | investorshub | 09/19/2023 7:04:28 PM |
$OKYO MomentumIts now last up | Sirpeter | investorshub | 09/19/2023 6:58:53 PM |
Price trading | mfayman | investorshub | 09/19/2023 5:58:51 PM |
good read | Count Crypto | investorshub | 09/19/2023 5:19:00 PM |
$OKYO The gaining last trade up | Sirpeter | investorshub | 09/19/2023 4:39:48 PM |
$OKYO short squeeze article | Sirpeter | investorshub | 09/19/2023 3:50:08 PM |
$OKYO short squeeze | mfayman | investorshub | 09/19/2023 3:27:45 PM |
$OKYO good read | Count Crypto | investorshub | 09/19/2023 2:55:58 PM |
Thoughts on where this is headed? | mfayman | investorshub | 09/19/2023 12:55:45 PM |
$OKYO MomentumIts gaining | mfayman | investorshub | 09/19/2023 12:34:50 PM |
$OKYO When is this gonna take off? | mfayman | investorshub | 09/19/2023 11:42:59 AM |
should we be shorting? | mfayman | investorshub | 09/19/2023 11:18:24 AM |
The now up | Sirpeter | investorshub | 09/19/2023 10:03:10 AM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...